The nontuberculous mycobacteria (NTM) cause miscellaneous disorders in humans, especially in the lungs, which present with a variety of radiological features. To date, knowledge of the pathogenic role of the Mycobacterium avium-intracellulare complex (MAC) in the human lung and the definitive criteria for initiating multidrug therapy are still lacking. However, there is little doubt that clarithromycin is the most efficacious drug among the various treatment regimens for lung NTM. In this study, with the use of a bridged nucleic acid (BNA) probe a detection system based on a real-time PCR (BNA-PCR) for the identification of the point mutations at position 2058 or 2059 in domain V of the 23S rRNA gene responsible for clarithromycin resistance was developed and has been assessed using MAC isolates from clinical samples. Out of 199 respiratory specimens, the drug susceptibility test demonstrated 12 strains resistant to clarithromycin, while the BNA-PCR showed 8 strains carrying the point mutation at position 2058 or 2059 of the 23S rRNA gene. This system revealed that there were mycobacterial strains resistant to clarithromycin which do not carry previously identified resistance genes. This paper documents a novel system for detecting clarithromycin-resistant strains and demonstrates that although these mutations are tacitly assumed to account for >90% of the reported resistant mutants, there is a significant fraction of resistant mutants that do not harbor these mutations. Therefore, unknown mechanisms affecting clarithromycin resistance remain to be elucidated.
T
he nontuberculous mycobacteria (NTM) are ubiquitous microorganisms found in various environments. They are capable of causing miscellaneous disorders in humans, especially in the lungs, which present with a variety of radiological features. It is noteworthy that the prevalence of lung NTM is increasing throughout the world (1, 2) . Whereas NTM diversity in clinical manifestations and geographic distribution has been well documented, Mycobacterium avium and Mycobacterium intracellulare, collectively referred to as the Mycobacterium avium-intracellulare complex (MAC), are frequently isolated from such patients in most countries (3) .
To date, knowledge of the pathogenic role of MAC strains in the human lung and the definitive criteria for initiating multidrug therapy are still lacking. However, there is little doubt that clarithromycin is the most efficacious drug among the various treatment regimens for lung NTM. Clarithromycin is a ribosome-targeting macrolide antibiotic that interacts with a bacterial 23S rRNA hairpin-like structure in domain II and the peptidyl transferase loop in domain V (4, 5) . Additionally, clarithromycin is the only agent for which susceptibility testing has high clinical efficacy. Therefore, management of clarithromycin-resistant MAC isolates from advanced lung NTM is an emerging concern. It is worth noting that multidrug therapy containing clarithromycin as the key drug is now a mandatory implementation to prevent resistance.
Other studies have concluded that the mechanism responsible for clarithromycin-resistant MAC emergence, although it has not been fully unraveled, is point mutations in domain V of the 23S rRNA gene (6, 7, 8) . It has been also reported that 4.0 to 10% of MAC organisms causing lung NTM are capable of acquiring clarithromycin resistance (6, 7) . Meanwhile, a great deal of attention has been paid to finding alternative ways to identify the clarithromycin-resistant genes in MAC isolates. Currently, culture-based drug susceptibility testing is the only means to evaluate the bioactivity of antibiotics against MAC strains despite the guideline recommendation that clarithromycin susceptibility testing be performed for all patients before therapy is initiated (3) . To this end, with a bridged nucleic acid (BNA) probe which has improved hybridizing capability between base pairs, a detection system for clarithromycin resistance mutations based on a real-time PCR (BNA-PCR) was developed and has been assessed using MAC isolated from clinical samples. In addition, the characteristics of patients with lung NMT who have the resistant organism were also studied.
MATERIALS AND METHODS
Clinical sample. Expectorated sputum was submitted to the microbiology laboratory at the Saitama Medical University Hospital, and an equal volume of Sputazyme (Kyokuto Pharmaceuticals Industrial Co., Ltd., Tokyo, Japan) was added for sputum lysis. The samples were centrifuged at 3,000 ϫ g for 20 min, and the pellet was first examined with Ziehl-Neelsen staining. Following N-acetyl-L-cysteine-sodium hydroxide (NALCNaOH) digestion and decontamination, the pellet of the sample was inoculated into BBL MGIT broth medium (BD, Tokyo, Japan), which was incubated in the Bactec MGIT 960 system (BD). After this incubation, M. avium or M. intracellulare was identified by the Cobas TaqMan 48 analyzer (Roche Diagnostics K.K., Tokyo, Japan). Two milliliters of the MGIT broth was analyzed by PCRs, and 500 l was transferred for drug susceptibility tests.
Drug susceptibility tests. The clarithromycin susceptibility of isolated M. avium or M. intracellulare was measured by BrothMIC NTM (Kyokuto Pharmaceuticals Industrial Co., Ltd., Tokyo, Japan), which employed a broth microdilution susceptibility panel containing 96 reagent wells and was in accordance with the current Clinical and Laboratory Standards Institute guidelines (9) . A week after 500 l of the MGIT broth was transferred to Myco broth (Kyokuto Pharmaceuticals Industrial Co., Ltd.), the Myco broth was split into each well (see the manufacturer's instructions for details). Strains with MICs of Յ8 g/ml at pH 7.4 were considered susceptible to clarithromycin, those with MICs of Ն32 g/ml were considered resistant, and those with MICs between 8 and 32 g/ml were considered intermediate.
DNA preparation. Two milliliters of MGIT broth containing M. avium or M. intracellulare was centrifuged at 3,000 ϫ g for 10 min, the pellet was mixed with 200 l of AL buffer (Qiagen, Tokyo, Japan) containing 20 l of proteinase K (TaKaRa Bio Inc., Shiga, Japan), and the resultant mixture was incubated at 56°C for 1 h. DNA was purified into 100 l of Tris-EDTA (TE) buffer with the QIAamp DNA blood minikit (Qiagen), according to the manufacturer's instructions (10) .
PCR.
The final solution of the PCR mixture contained 12.5 l of the TaKaRa Premix Ex Taq (TaKaRa Bio Inc., Shiga, Japan), 300 nM each primer, 300 nM fluorescence-labeled TaqMan probe, 1.0 l of purified DNA from MGIT broth, and deionized distilled water up to 25.0 l. Two real-time PCRs were simultaneously performed to detect the clarithromycin resistance gene using the BNA-PCR and to identify M. avium or M. intracellulare as a control using the TaqMan probe (11) . The PCR was performed by starting at 95°C for 30 s followed by 40 cycles at 95°C for 5 s and 66°C for 40 s using the SmartCycler II (Cepheid, Sunnyvale, CA). The sequences of primers and probes are described in Table 1 . The electrophoresis was carried out with a 100-bp DNA ladder (TaKaRa Bio Inc.) in a 1.5% agarose gel containing 0.5 g/ml ethidium bromide.
Resistance gene synthesis. Template DNA for the resistance gene, a 237-bp fragment from position 2415 through 2650 in the 23S rRNA gene of Mycobacterium avium (GenBank accession number X74494) harboring the sequences of both the MAV_Fw2485 and MAV_Rv2631 regions, was generated at TaKaRa Bio Inc. A point mutation (A¡G, C, or T) was inserted at position 2058 or 2059 equivalent to Escherichia coli (GenBank accession number AF053966.1). A set of resistance genes showing 2 bp before or after position 2058 and 2059 are depicted in Fig. 1 .
Nucleotide sequencing. PCR products from the BNA-PCR were purified by a StrataPrep PCR purification kit (Agilent Technologies, Santa Clara, CA, USA) and then subjected to sequence analysis using MAV_Fw2485 at Fasmac Co., Ltd. (Kanagawa, Japan). The sequence analysis of the domain II and domain V regions in 23S rRNA was done with MAV_Fw1073, MAV_Fw1533, and MAV_Fw12938 (Table 1) .
Ethical considerations. The research protocol involving patients' samples was reviewed by the institutional review boards of the Saitama Medical University Hospital (institutional review board [IRB] number 11-006, 9 June 2011). 
RESULTS

Development of a detection system for the clarithromycin resistance gene by BNA-PCR.
The primary factor resulting in clarithromycin resistance in M. avium or M. intracellulare has been reported to be point mutations at position 2058 or 2059 in domain V of the 23S rRNA gene; the position number corresponds to the 23S rRNA gene of E. coli (6, 7, 12) . Current clinical laboratory techniques have enabled the detection of gene mutations readily and effortlessly. A variety of techniques have now been employed for the detection of mutations in a clinical setting (13, 14) . BNAs are artificial nucleic acids with a high binding affinity to a specific sequence and enhanced biochemical stability (15, 16) . With this technique, even a single mismatch sequence was able to be discriminated from the amplified product. Hence, we designed a real-time PCR-based system employing BNA probes, in which two BNA bases were introduced at positions 2058 and 2059 (-gaAAag-) to detect the clarithromycin resistance gene of MAC isolates (BNAs are underlined) (Fig. 1) . If a point mutation exists, the resulting sequence mismatch leads to a decrease in the melting temperature (T m ) value. This prevents the BNA probe from annealing to the PCR product and consequently reduces the emitted fluorescence level. Additionally, the established real-time PCR using a TaqMan probe to identify M. avium or M. intracellulare was simultaneously performed as a positive control (10, 11) (Fig. 1A) . Analyzing the specificity of the BNA-PCR for MAC. In order to assess the analytical specificity of this system, first the BNA-PCR and the TaqMan PCR were both tested against a cross-reactivity panel. The panel contains DNA from 76 organisms (14) and showed that both the BNA-PCR and the TaqMan-PCR for M. avium and M. intracellulare amplified the M. avium and M. intracellulare strains specifically, respectively, with no cross-reaction with other organisms. Next, 237-bp DNA of wild type (WT) (-gaAAag-) and six forms of point mutations (-gaACag-, -gaAGag-, -gaATag-, -gaCAag-, -gaGAag-, and -gaTAag-) were synthesized (Fig. 1B) . With these oligonucleotides, BNA-PCR was capable of reacting to the amplicon of WT strains but not the mutants. Additionally, the target sequences were well amplified by primer pairs using MAV_Fw2485 and MAV_Rv2631 and were confirmed by gel electrophoresis (Fig. 1C) . These data show that BNA-PCR was able to discriminate the WT from the mutant oligonucleotides.
Features of patients with lung NTM from whom clarithromycin-resistant MAC strains were isolated. In order to confirm whether this system worked with clinical samples and to assess the prevalence of clarithromycin-resistant MAC infections, respiratory samples were collected from patients who visited the Saitama Medical University Hospital and were suspected of or diagnosed as having lung NTM. The study was performed between 9 June 2011 and 9 June 2015, and a total of 199 sputum samples were analyzed. The sputum samples were digested and then aliquoted for a drug susceptibility test and BNA-PCR as shown in the schematic diagram in Fig. 2 . Out of 199 strains, 12 strains were demonstrated to be resistant to clarithromycin by the drug susceptibility test, while the BNA-PCR showed 8 strains carrying point mutations at position 2058 of the 23S rRNA gene ( Table 2 ). The characteristics of the patients who had clarithromycin-resistant MAC infections are summarized in Table 3 . This shows that a female of lighter build had a greater tendency than a male to be affected by a clarithromycin-resistant MAC infection even in the absence of a smoking habit or other underlying conditions as previously indicated (6); however, all physical features resembled those of individuals who had clarithromycin-susceptible MAC infections (17) . In addition, although the data from patients were gathered retrospectively, they indicate that macrolide monotherapy might result in the development of the resistant strain: half of the patients with clarithromycin-resistant MAC infections had received monotherapy. Indeed, 3 out of 12 patients who had resistant MAC infections died due to the progression of lung NTM and subsequent deterioration of lung function.
Detection of other mutations causing clarithromycin resistance in MAC. Some data were inconsistent with previous reports that mutations at position 2058 or 2059 of the 23S rRNA gene accounted for most of clarithromycin-resistant MAC strains (6, 7, 8, 12) . Therefore, sequence analysis of the PCR product that showed clarithromycin resistance was implemented and showed that the clarithromycin-resistant samples, except for eight mutant specimens, were WT (-gaAAag-). Based on the this result, other possibilities for the development of clarithromycin resistance were subsequently examined. It has been reported that point mutations at position 752 in the hairpin-like structure in domain II as well as at positions 2062 and 2505 at the peptidyl transferase loop in domain V of 23S rRNA were involved in the clarithromycin resistance of E. coli (18) . Therefore, the sequence of domain II covering the position 752 was scrutinized using primer MAV_Fw1073 (Table 2) . Similarly, the sequences of positions 2062 and 2505 were examined using primers MAV_Fw2485 and MAV_Fw2938, respectively ( Table 2 ). The 12 clarithromycinresistant MAC strains and a randomly selected 10 clarithromycinsensitive MAC strains were analyzed and showed no mutations in domain II and domain V of 23S rRNA. Likewise, the mutations of
FIG 2
Procedure for the BNA-PCR and drug susceptibility test. In step 1, M. avium or M. intracellulare was isolated from the respiratory specimens using liquid culture (BBL MGIT). In step 2, the culture media were divided into two tests. One was submitted for two real-time PCRs, which were simultaneously performed to detect the clarithromycin (CAM) resistance gene using the BNA probe and to identify M. avium or M. intracellulare using the TaqMan probe, and the other was submitted for drug susceptibility testing. In step 3, sequence analysis was conducted for the clarithromycin-resistant strains. nucleotides 1198 through 1247 at the hairpin-like structure in domain II have been reported to introduce macrolide resistance in E. coli (19) . Thus, the sequence between 1198 and 1247 was also analyzed using primer MAV_Fw1533 (Table 2) . No mutations in this sequence were detected.
DISCUSSION
In this work, we set out to develop a real-time PCR-based clarithromycin resistance gene detection system using BNAs. An additional goal was to assess its efficacy using clinical samples from patients with lung NTM. Although our technique should be validated against the various techniques currently available, one of the advantages in applying BNAs is that the BNA-PCR can be simultaneously implemented with most conventional PCR systems since all of the reaction steps for the BNA-PCR are the same as those of ordinary PCR. Therefore, this technique not only enables the detection of mutations within the target gene but also allows for the use of existing devices. Moreover, the BNA-PCR was readily applicable to clinical practice; the consumables cost $20 US per sample, and the results can be delivered within 4 h after Mycobacterium species are grown. Thus, considering the increase in the number of patients with lung NTM and the ease of implementation of this system using existing devices, it is practical and perhaps advisable that clinical laboratories employ this system to address the growing demand for the identification of clarithromycin-resistant MAC strains. In prokaryotic cells, rRNAs that serve as the sites for protein synthesis are composed of three distinct size species of rRNA (23S, 16S, and 5S). The ribosomal peptidyl transferase activity resides in domain V of 23S rRNA. Domain V is also the most common binding site for antibiotics and accounts for macrolide resistance in a variety of bacteria (5, 20, 21) . Indeed, an abundance of literature reports suggest that point mutations at either position 2058 or 2059 in the 23S rRNA gene are the most responsible for macrolide-resistant MAC strain (6, 7, 8, 12, 22, 23) . However, our results indicate that some of the resistance did not arise from the mutations in domain V. Given the inherent diversity in the mechanisms of pathogenicity displayed by MAC strains, it is conceivable and likely that there are other mutations that can result in the emergence of resistance. In line with this, it has been reported that the mutations of nucleotides 1198 through 1247 or of position 752 in domain II or point mutations at positions 2062 and 2505 in domain V of 23S rRNA are involved in macrolide resistance in E. coli. With this in mind, those mutations were scrutinized using clarithromycin-resistant NTM. However, this investigation demonstrated no further mutants. At least one strain showing clarithromycin resistance but carrying no mutation at position 2058 or 2059 has been observed in separate reports using clinical samples (6, 7, 8) . This implies that other underlying mechanisms causing clarithromycin resistance undoubtedly exist in MAC strains.
Clarithromycin-resistant MAC disease emerges as a threat to treatment and requires a more complicated strategy. This is in part due to the fact that there has been no reliable in vitro drug susceptibility evaluation yet. Surgical intervention should be considered first if the patient can tolerate such an invasive procedure. The majority of patients, however, are already compromised due to the progressive disorder and destruction of lung function. Lung transplant, although still somewhat of a contraindication, may be one potential treatment for lung NTM infection (24) . Indeed, lung transplantation has been performed in patients with cystic fibrosis who carried MAC (25, 26) . Although it should be noted that posttransplant immunosuppressive management together with antimycobacterials lacking competent macrolide ability raises the possibility of reemergence of resistant MAC infections in the donor lung. Despite a paucity of reliable studies, treatment against MAC strains resistant to clarithromycin should be initiated using medication that has not been previously used in the patient. The regimen should be composed of at least three or four antimycobacterials, including a parenteral aminoglycoside, high-dose ethambutol (6), rifabutin (3), fluoroquinolones acting against DNA gyrase and topoisomerase IV (27, 28) , and clofazimine (28, 29) . Although somewhat controversial, continuation of macrolide treatment, even at a lower dose, if well tolerated, may also be considered due to its broad mechanism of action.
Our experiment has shown that the BNA-PCR system, established to identify the clarithromycin resistance gene, also elucidated the existence of clarithromycin-resistant MAC strains carrying no mutation at position 2508 or 2509. The disease-causing processes of Mycobacterium species are still poorly understood, and these bacteria also show an abundance of diversity in their regional characteristics and in the individuals more likely to be affected. Since clarithromycin is a final weapon against lung disorders due to MAC, the exact mechanism for the clarithromycin resistance requires further investigation.
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